William Blair Comments on Amgen's Q1 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for Amgen in a research report issued to clients and investors on Wednesday, March 5th. William Blair analyst M. Phipps anticipates that the medical research company will earn $4.42 per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen's Q2 2026 earnings at $5.00 EPS and Q3 2026 earnings at $5.24 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%.

A number of other brokerages have also commented on AMGN. Truist Financial decreased their price target on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Bank of America lifted their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $314.04.

Remove Ads

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $8.47 on Friday, hitting $318.89. The company had a trading volume of 3,079,086 shares, compared to its average volume of 2,553,757. The stock has a 50 day moving average price of $287.50 and a 200 day moving average price of $299.50. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market cap of $171.31 billion, a price-to-earnings ratio of 42.24, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 2.99%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 over the last quarter. 0.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Capital Performance Advisors LLP bought a new stake in Amgen during the third quarter worth about $25,000. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the 4th quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in Amgen in the 4th quarter worth approximately $26,000. Legacy Investment Solutions LLC bought a new position in Amgen during the third quarter valued at approximately $29,000. Finally, Ritter Daniher Financial Advisory LLC DE raised its stake in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.